Work

Phase II study of ipilimumab (IPI) in children and adolescents with unresectable stage III or IV malignant melanoma (MEL).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.e21006

Authors: Alberto S. Pappo, Christophe Bergeron, Lia Gore, Leonard S. Sender, Ira J. Dunkel, Cynthia E. Herzog, Lieve Brochez, Ofelia Cruz, Karsten Nysom, Elmer Berghorn, Burcin Simsek, Jun Shen, Birgit Geoerger

Institutions: St. Jude Children's Research Hospital, Institut d’Hématologie et d’Oncologie Pédiatrique, Centre Léon Bérard, Children's Hospital Colorado, University of Colorado Anschutz, Children's Hospital of Orange County, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Ghent University Hospital, Hospital Sant Joan de Déu Barcelona, Copenhagen University Hospital, Rigshospitalet, Bristol-Myers Squibb (United States), Institut Gustave Roussy

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891362708

Cites:

Cited by: 1

Related to: 10